Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Earnings Results

Ultragenyx Pharmaceutical (NASDAQ:RARE) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07), Zacks reports. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%.

Ultragenyx Pharmaceutical Stock Performance

RARE traded up $0.09 during midday trading on Thursday, hitting $43.52. The stock had a trading volume of 783,997 shares, compared to its average volume of 887,558. The company has a market cap of $4.02 billion, a P/E ratio of -6.73 and a beta of 0.60. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37. The business has a fifty day moving average of $43.81 and a 200 day moving average of $49.59.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the completion of the sale, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600. This represents a 0.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 5.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wedbush reiterated a “neutral” rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Piper Sandler upped their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. JPMorgan Chase & Co. cut their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 21st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.43.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.